Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. During the recent MedCity News INVEST Digital Health conference, Dr. Brigham Hyde, CEO and co-founder of Atropos Health, spoke on a panel joined by David Latshaw, CEO and co-founder of BioPhy, and moderated by Naomi Fried, CEO of PharmStars, to discuss these applications and more.

Read the full article